Trav41: A Potential Drug Target for Various Diseases (G28640)

Target Name: TRAV41

NCBI ID: G28640

TRAV41

Other Name(s): TCRAV41S1 | T cell receptor alpha variable 41 | TCRAV19S1

Trav41: A Potential Drug Target for Various Diseases

Trav41 (TRAV41S1) is a drug target (or biomarker) that is being studied for its potential role in treating various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

Trav41 is a small protein that is expressed in many different tissues throughout the body, including the brain, lungs, heart, and kidneys. It is a key regulator of cell growth and differentiation, and has been shown to play a role in a variety of diseases.

One of the things that makes Trav41 an attractive drug target is its ability to interact with a variety of different proteins, including some that are known to be involved in cancer, neurodegenerative disorders, and autoimmune diseases. This makes it possible that Trav41 could be used to treat a wide range of diseases, rather than just one or two.

For example, Trav41 has been shown to interact with the protein PDGF-BB, which is involved in cell growth and differentiation, as well as with the protein NF-kappa-B, which is involved in inflammation and immune responses. These interactions could make Trav41 a potential treatment for diseases that are caused by problems with cell growth, differentiation, or inflammation.

Another way in which Trav41 is being studied as a drug target is its ability to modulate the activity of cells. For example, Trav41 has been shown to reduce the activity of cancer cells, and to increase the activity of healthy cells. This could make Trav41 an attractive treatment for diseases that are caused by the uncontrolled activity of cancer cells.

In addition to its potential as a drug target, Trav41 is also being studied as a biomarker. This means that researchers are using Trav41 as a tool to study the effects of drugs on different tissues and cells, in order to better understand how the drug is working and how it could be used to treat different diseases.

One of the things that makes Trav41 an attractive biomarker is its stability and its ability to be easily measured in different tissues and cells. This makes it possible to study the effects of drugs on Trav41 levels and how they are related to the effects of the drugs on different tissues and cells.

Overall, Trav41 is an interesting drug target (or biomarker) that is being studied for its potential role in treating a variety of diseases. Its ability to interact with different proteins and to modulate the activity of cells makes it a promising candidate for use as a drug or biomarker. Further research is needed to fully understand the effects of Trav41 on different tissues and cells, and to determine its safety and effectiveness as a treatment for different diseases.

Protein Name: T Cell Receptor Alpha Variable 41

Functions: V region of the variable domain of T cell receptor (TR) alpha chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRAV41 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRAV41 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets